Prognostic factors in patients with operable breast cancer who received neoadjuvant chemotherapy

被引：0
|
作者：
Horiguchi, J. [1 ]
Takata, D. [1 ]
Nagaoka, R. [1 ]
Fujii, T. [1 ]
Sato, A. [1 ]
Tokiniwa, H. [1 ]
Higuchi, T. [1 ]
Uchida, S. [1 ]
Tsuboi, M. [1 ]
Yajima, R. [1 ]
Kikuchi, M. [1 ]
Ino, Y. [2 ]
Oyama, T. [3 ]
机构：
[1] Gunma Univ Hosp, Breast & Endocrine Surg, Maebashi, Gunma, Japan
[2] Kusunoki Hosp, Surg, Fujioka, Japan
[3] Gunma Univ Hosp, Pathol, Maebashi, Gunma, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
337
引用
收藏
页码：S94 / S94
页数：1
相关论文
共 50 条
  • [1] Circulating tumour cells in patients with operable breast cancer who received neoadjuvant chemotherapy
    Horiguchi, J.
    Takata, D.
    Rokutanda, N.
    Nagaoka, R.
    Sato, A.
    Tokiniwa, H.
    Uchida, S.
    Ogino, M.
    Iino, Y.
    Takeyoshi, I.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S53 - S54
  • [2] Prognostic factors for patients with invasive ductal carcinoma of the breast who received neoadjuvant chemotherapy
    Tamura, N.
    [J]. BREAST, 2009, 18 : S33 - S33
  • [3] Prognostic factors for patients with invasive ductal carcinoma of the breast who received neoadjuvant chemotherapy
    Tamura, N.
    Tamura, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy
    Iwase, Toshiaki
    Parikh, Aaroh
    Dibaj, Seyedeh S.
    Shen, Yu
    Shrimanker, Tushaar Vishal
    Chainitikun, Sudpreeda
    Kida, Kumiko
    Sapon, Maryanne E.
    Sahin, Onur
    James, Anjali
    Medrano, Andrea Yizel Delgado
    Klopp, Ann H.
    Ueno, Naoto T.
    [J]. CANCERS, 2021, 13 (04) : 1 - 11
  • [5] STUDY OF PATIENTS WITH STAGE III BREAST CANCER WHO RECEIVED NEOADJUVANT CHEMOTHERAPY
    Iwakuma, N.
    Toh, U.
    Takahashi, R.
    Mishima, M.
    Takenaka, M.
    Koura, K.
    Fujii, T.
    Shirouzu, K.
    [J]. BREAST, 2013, 22 : S102 - S102
  • [6] Prognostic role of EGFR in stage II or III breast cancer patients who received neoadjuvant chemotherapy.
    Keam, B.
    Kim, H-J
    Oh, D-Y
    Lee, S-H
    Kim, D-W
    Han, W.
    Im, S-A
    Kim, T-Y
    Park, IAe
    Noh, D-Y
    Heo, D. S.
    Bang, Y-J
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S93 - S93
  • [7] Prognostic factors in breast cancer patients following neoadjuvant chemotherapy
    Kim, JR
    Chang, ES
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2005, 59 : S395 - S396
  • [8] Prognostic factors in breast cancer patients following neoadjuvant chemotherapy
    Kim, J.
    Lee, J.
    Kim, H.
    Chang, E.
    [J]. BREAST, 2007, 16 : S29 - S29
  • [9] Prognostic factors for response to neoadjuvant chemotherapy in patients with breast cancer
    Kang, S. Y.
    Jung, Y. S.
    Kim, K. S.
    [J]. BREAST, 2011, 20 : S48 - S48
  • [10] Neoadjuvant chemotherapy for operable breast cancer
    Mieog, J. S. D.
    van der Hage, J. A.
    de Velde, C. J. H. van
    [J]. BRITISH JOURNAL OF SURGERY, 2007, 94 (10) : 1189 - 1200
12345